This study provides a global overview of activities and impacts of product development partnerships (PDPs), including MMV.
The study, commissioned by the UK’s Foreign, Commonwealth & Development Office (FCDO), assesses development of new medicines and technologies for 35 poverty-related and neglected diseases. The recommendations collectively demonstrate that an alternative R&D model to a purely private sector approach is feasible and has been transformational. It has resulted in 85 new products to market,including 3 vaccines, 27 therapeutics, 50 diagnostics or health technologies, and 5 vector control tools, with cumulative investments of less than US$ 5 billion over the period 2007-2018, for the 10 PDPs examined. The evidence clearly supports a need to increase, sustain and better coordinate R&D funding for poverty related and neglected diseases through PDPs.